| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.31M | 2.22M | 4.23M | 1.12M | 0.00 | 0.00 |
| Gross Profit | -8.72M | -17.84M | -4.39M | -1.71M | -1.97M | -1.78M |
| EBITDA | 19.13M | 12.33M | -9.76M | -5.97M | -5.67M | -4.21M |
| Net Income | 11.43M | 11.69M | -6.97M | -5.31M | -15.10M | -722.18K |
Balance Sheet | ||||||
| Total Assets | 61.51M | 71.98M | 42.99M | 25.70M | 8.25M | 27.94M |
| Cash, Cash Equivalents and Short-Term Investments | 15.93M | 20.44M | 6.11M | 4.95M | 6.23M | 12.48M |
| Total Debt | 635.42K | 711.50K | 2.42M | 1.42M | 720.63K | 251.34K |
| Total Liabilities | 1.88M | 1.90M | 5.67M | 2.59M | 1.49M | 3.33M |
| Stockholders Equity | 59.74M | 70.16M | 37.31M | 22.64M | 6.24M | 24.67M |
Cash Flow | ||||||
| Free Cash Flow | -4.13M | -8.49M | -7.60M | -6.77M | -6.26M | 9.44M |
| Operating Cash Flow | -4.75M | -9.04M | -7.16M | -6.57M | -5.83M | 9.50M |
| Investing Cash Flow | 1.83M | 22.89M | -8.20M | -16.38M | -423.39K | -62.13K |
| Financing Cash Flow | 587.37K | 69.30K | 17.76M | 21.68M | 0.00 | 250.96K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $76.81M | 10.44 | 8.43% | ― | 8.47% | -32.22% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
63 Neutral | $29.50M | 6.09 | 9.56% | 6.45% | 214.07% | -40.88% | |
61 Neutral | $49.15M | 0.55 | -29.28% | ― | ― | ― | |
55 Neutral | $31.76M | 2.72 | 25.75% | ― | 121.21% | ― |
On February 1, 2026, MDB Capital Holdings, LLC appointed 73-year-old investment veteran Jeb Terry Sr. as an independent director and member of its audit committee, with his initial term running until the company’s next annual meeting of stockholders. Terry, who has over two decades of experience investing in microcap medical and biotechnology companies and a background spanning venture capital, private equity, banking, and hedge fund management, was selected for his extensive work as a registered investment adviser and his ability to source small-cap opportunities, and has been deemed both an independent director under Nasdaq standards and a financial expert. As part of his compensation, he will receive a $50,000 annual cash payment and options for up to 100,000 Class A shares that vest over time, subject to continued service and the company’s clawback policy. Also effective February 1, 2026, long-serving director Susanne Meline resigned from the board to pursue retirement, a change that marks both a generational transition in board composition and a bolstering of financial and microcap investment expertise at the board and audit committee level for MDB Capital’s stakeholders.
The most recent analyst rating on (MDBH) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on MDB Capital Holdings, LLC Class A stock, see the MDBH Stock Forecast page.
On December 2, 2025, MDB Capital Holdings, LLC held its Annual Meeting of Stockholders, where shareholders elected seven directors to serve until the 2026 meeting and ratified RBSM LLP as the independent accounting firm for the fiscal year ending December 31, 2025. The meeting saw a significant turnout, with 84.90% of eligible votes represented, and all proposals passed without broker non-votes, indicating strong shareholder support for the company’s governance and financial oversight decisions.
The most recent analyst rating on (MDBH) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on MDB Capital Holdings, LLC Class A stock, see the MDBH Stock Forecast page.